Related references
Note: Only part of the references are listed.Another New Antibiotic for Skin Infections and Why Infectious Disease Specialists Are Hypocrites
Loren G. Miller
CLINICAL INFECTIOUS DISEASES (2019)
Antimicrobial stewardship during a time of rapid antimicrobial development: Potential impact on industry for future investment
Lucas T. Schulz et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Sustainable Discovery and Development of Antibiotics - Is a Nonprofit Approach the Future?
Travis B. Nielsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
New antibiotics: NHS will test pay for usefulness model to stimulate research
Zosia Kmietowicz
BMJ-BRITISH MEDICAL JOURNAL (2019)
Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data
Cornelius J. Clancy et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
The quality of studies evaluating antimicrobial stewardship interventions: a systematic review
V. A. Schweitzer et al.
CLINICAL MICROBIOLOGY AND INFECTION (2019)
Delivering precision antimicrobial therapy through closed-loop control systems
T. M. Rawson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Studying new antibiotics for multidrug resistant infections: are today's patients paying for unproved future benefits?
John H. Powers et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Rapid diagnostics for bloodstream infections: A primer for infection preventionists
Charles E. Edmiston et al.
AMERICAN JOURNAL OF INFECTION CONTROL (2018)
Murepavadin: a new antibiotic class in the pipeline
Ignacio Martin-Loeches et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection The TANGO I Randomized Clinical Trial
Keith S. Kaye et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Metrics of Antimicrobial Stewardship Programs
Amy L. Brotherton
MEDICAL CLINICS OF NORTH AMERICA (2018)
Current and Future Opportunities for Rapid Diagnostics in Antimicrobial Stewardship
Tristan T. Timbrook et al.
MEDICAL CLINICS OF NORTH AMERICA (2018)
New Molecular Diagnostic Approaches to Bacterial Infections and Antibacterial Resistance
Ephraim L. Tsalik et al.
ANNUAL REVIEW OF MEDICINE, VOL 69 (2018)
Studying new antibiotics for multidrug resistant infections: are today's patients paying for unproved future benefits?
John H. Powers et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
The Current State of Antimicrobial Stewardship: Challenges, Successes, and Future Directions
Jennifer Emberger et al.
CURRENT INFECTIOUS DISEASE REPORTS (2018)
Role of the Pharmacist in Antimicrobial Stewardship
Diane M. Parente et al.
MEDICAL CLINICS OF NORTH AMERICA (2018)
Role of pharmacists in antimicrobial stewardship programmes
Javier Garau et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2018)
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink et al.
INFECTIOUS DISEASES AND THERAPY (2018)
Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach
Matteo Bassetti et al.
INTENSIVE CARE MEDICINE (2017)
Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps
Victoria L. Simpkin et al.
JOURNAL OF ANTIBIOTICS (2017)
Integrated Stewardship Model Comprising Antimicrobial, Infection Prevention, and Diagnostic Stewardship (AID Stewardship)
J. H. Dik et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2017)
White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs
Helen W. Boucher et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis
David Baur et al.
LANCET INFECTIOUS DISEASES (2017)
Preclinical antibiotic pipeline gets a pick-me-up
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2017)
Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile-Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation
Kelly R. Reveles et al.
PHARMACOTHERAPY (2017)
Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature
Ryan K. Shields et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation
Shawn H. MacVane et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
What is antimicrobial stewardship?
O. J. Dyar et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance
Christine Ardal et al.
CLINICAL INFECTIOUS DISEASES (2017)
Challenges and Opportunities of Nontraditional Approaches to Treating Bacterial Infections
Brian N. Tse et al.
CLINICAL INFECTIOUS DISEASES (2017)
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis
Marya D. Zilberberg et al.
BMC INFECTIOUS DISEASES (2017)
The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations
S. D. Goldenberg et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2016)
Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of US Food and Drug Administration-Approved Antibiotics, 2010-2015
Dalia Deak et al.
ANNALS OF INTERNAL MEDICINE (2016)
Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks
Anthony McDonnell et al.
CLINICAL INFECTIOUS DISEASES (2016)
Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America
Tamar F. Barlam et al.
CLINICAL INFECTIOUS DISEASES (2016)
Measuring the impact of antimicrobial stewardship programs
Jan-Willem H. Dik et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2016)
Noninferior Antibiotics: When Is Not Bad Good Enough?
Mark J. DiNubile
OPEN FORUM INFECTIOUS DISEASES (2016)
How to Pitch an Antibiotic Stewardship Program to the Hospital C-Suite
Brad Spellberg et al.
OPEN FORUM INFECTIOUS DISEASES (2016)
Advances in antibiotic therapy in the critically ill
Jean-Louis Vincent et al.
CRITICAL CARE (2016)
A Review of Quality Measures for Assessing the Impact of Antimicrobial Stewardship Programs in Hospitals
Mary Richard Akpan et al.
ANTIBIOTICS-BASEL (2016)
Clinical and Economic Benefits of Fidaxomicin Compared to Vancomycin for Clostridium difficile Infection
Jason C. Gallagher et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis
Gowri Raman et al.
BMC INFECTIOUS DISEASES (2015)
Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain
C. Rubio-Terres et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2015)
The human gut resistome
Willem van Schaik
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2015)
Innovation of Novel Antibiotics: An Economic Perspective
Michael R. McKellar et al.
CLINICAL INFECTIOUS DISEASES (2014)
Demonstrating the Value of Antimicrobial Stewardship Programs to Hospital Administrators
Jerod L. Nagel et al.
CLINICAL INFECTIOUS DISEASES (2014)
Antimicrobial Stewardship: Philosophy Versus Practice
Elizabeth S. Dodds Ashley et al.
CLINICAL INFECTIOUS DISEASES (2014)
Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials
Stuart Johnson et al.
CLINICAL INFECTIOUS DISEASES (2014)
Review of Rapid Diagnostic Tests Used by Antimicrobial Stewardship Programs
Karri A. Bauer et al.
CLINICAL INFECTIOUS DISEASES (2014)
Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future
Magnus Unemo et al.
CLINICAL MICROBIOLOGY REVIEWS (2014)
Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
Dilip Nathwani et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
Jason A. Roberts et al.
LANCET INFECTIOUS DISEASES (2014)
Antibiotic stewardship in the intensive care unit
Charles-Edouard Luyt et al.
CRITICAL CARE (2014)
Antimicrobial Stewardship Programs in Florida's Acute Care Facilities
Lilian Abbo et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2013)
Impact of formulary restriction with prior authorization by an antimicrobial stewardship program
Erica E. Reed et al.
VIRULENCE (2013)
Antimicrobial stewardship programs (ASPs) The devil is in the details
Cheston B. Cunha et al.
VIRULENCE (2013)
Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection
Michelle M. Nerandzic et al.
CLINICAL INFECTIOUS DISEASES (2012)
Can we identify patients at high risk of recurrent Clostridium difficile infection?
C. P. Kelly
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
Oliver A. Cornely et al.
LANCET INFECTIOUS DISEASES (2012)
Novel classes of antibiotics or more of the same?
Anthony R. M. Coates et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Improving Antimicrobial Stewardship: The Evolution of Programmatic Strategies and Barriers
Birgir Johannsson et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2011)
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Thomas J. Louie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Relationship of Carbapenem Restriction in 22 University Teaching Hospitals to Carbapenem Use and Carbapenem-Resistant Pseudomonas aeruginosa
Amy L. Pakyz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Impact of antibiotic restrictions: the ethical perspective
J. Garau
CLINICAL MICROBIOLOGY AND INFECTION (2006)
Nosocomial antibiotic resistance in multiple gram-negative species: Experience at one hospital with squeezing the resistance balloon at multiple sites
JJ Rahal et al.
CLINICAL INFECTIOUS DISEASES (2002)
Share Paper
